Wright Medical commenced U.S. launch of the PROstep™ Minimally Invasive Surgery System and AUGMENT® Injectable Bone Graft.
PROstep features implants and instrumentation to treat forefoot and hindfoot pathologies, including Hallux Valgus. As noted in the company’s 1Q18 earnings call, this is slated as the biggest product launch for the company in the past several years. It is expected to have high adoption in ambulatory surgical centers.
AUGMENT Injectable is reportedly the first clinically-proven injectable protein therapeutic on the U.S. market; it offers an alternative to harvested autograft in ankle and hindfoot fusion. This injectable version of AUGMENT gained FDA premarket approval in June 2018.
Further, the company marked the milestone of over 30,000 total ankle replacement procedures globally since 2008. The company’s ankle line includes INBONE™ and INFINITY™ total ankles, INVISION™ Total Ankle Revision and the PROPHECY™ Preoperative Navigation System. INBONE was acquired in 2008 with the purchase of INBONE Technologies. INFINITY launched in 2014, INVISION followed in 2017 and in 1Q18, the company launched INVISION PROPHECY Preoperative Navigation for Total Ankle Revision, a pre-op planning system with patient-specific instrumentation.
Wright Medical commenced U.S. launch of the PROstep™ Minimally Invasive Surgery System and AUGMENT® Injectable Bone Graft.
PROstep features implants and instrumentation to treat forefoot and hindfoot pathologies, including Hallux Valgus. As noted in the company's 1Q18 earnings call, this is slated as the biggest product launch for the company in...
Wright Medical commenced U.S. launch of the PROstep™ Minimally Invasive Surgery System and AUGMENT® Injectable Bone Graft.
PROstep features implants and instrumentation to treat forefoot and hindfoot pathologies, including Hallux Valgus. As noted in the company’s 1Q18 earnings call, this is slated as the biggest product launch for the company in the past several years. It is expected to have high adoption in ambulatory surgical centers.
AUGMENT Injectable is reportedly the first clinically-proven injectable protein therapeutic on the U.S. market; it offers an alternative to harvested autograft in ankle and hindfoot fusion. This injectable version of AUGMENT gained FDA premarket approval in June 2018.
Further, the company marked the milestone of over 30,000 total ankle replacement procedures globally since 2008. The company’s ankle line includes INBONE™ and INFINITY™ total ankles, INVISION™ Total Ankle Revision and the PROPHECY™ Preoperative Navigation System. INBONE was acquired in 2008 with the purchase of INBONE Technologies. INFINITY launched in 2014, INVISION followed in 2017 and in 1Q18, the company launched INVISION PROPHECY Preoperative Navigation for Total Ankle Revision, a pre-op planning system with patient-specific instrumentation.
Copy to clipboard 
